CD19 and acute lymphoblastic leukemia: Two CAR T-cell therapies have been approved for clinical use (KymriahTM and YescartaTM), both of which target CD19-expressing tumor cells for use in acute lymphoblastic leukemia and B-cell Lymphomas [62].